News Daily News Positive Top-line Results for Retatrutide in Diabetes: TRANSCEND-T2D-1 Caitlin E. Cox March 19, 2026
News Daily News Ultraprocessed Food Again Linked to Higher CVD Risk: MESA Michael O'Riordan March 17, 2026
News Daily News Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone Michael O'Riordan March 03, 2026
News Daily News Both Low-fat and Low-carb Diets Tied to Less Heart Disease Michael O'Riordan February 11, 2026
News Daily News Weight Regained Within 18 Months of Stopping GLP-1 Drugs Michael O'Riordan January 08, 2026
News Daily News SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide Michael O'Riordan December 18, 2025
News Daily News Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER Michael O'Riordan December 12, 2025
News Daily News High Aerobic Fitness Linked to Less Chronic Disease in Later Life Michael O'Riordan October 10, 2025
News Daily News Risk Factors Present in Nearly All Patients Who Develop CVD Michael O'Riordan October 02, 2025
News Daily News CVD Still the Leading Cause of Death and Disease Globally Michael O'Riordan September 24, 2025
News Daily News Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s Michael O'Riordan September 18, 2025
News Daily News AI-Supported Coaching Shows Promise for Improving Glycemic Control L.A. McKeown August 25, 2025
News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025
News Daily News PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors Michael O'Riordan July 18, 2025
News Daily News Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC Michael O'Riordan June 25, 2025
News Daily News Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board Michael O'Riordan June 25, 2025
News Daily News Majority of US Adults Have High Long-term Risk of CVD: NHANES Michael O'Riordan June 13, 2025